First marketing authorization submission for blarcamesine NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...

A team of surgeons from various medical specialties, including neurology, neurosurgery, critical care, and ICU, successfully ...

Parkinson’s disease is a brain disorder that affects about one million people in the U.S. It happens when the brain loses ...

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of ...

Acadia is on track to achieve over $1 billion in annualized sales in 2025. The next phase of growth could come from two ...

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness ...

In the study, the freezing of gait was fully resolved in one of the two low-dose subjects and in all high-dose subjects.